Skip to Content
Home > About Us > Research and Grants Administration > Results
This registry/tissue bank is focused on the collection of detailed information and biological samples on participants to help create a resource that will be helpful to researchers in future studies related to breast cancer.
The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.
The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).
The purpose of this research study is to look at lung cancer patients’ tumors that were removed by surgery for certain genetic changes, and to possibly offer these patients a treatment study with drugs that may specifically target tumors that have these genetic changes.
The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for patients with ALK-positive non-small cell lung cancer.
The purpose of this study is to compare any good and bad effects of receiving the drugs dabrafenib and trametinib continuously to receiving dabrafenib and trametinib with a break in treatment for patients with BRAF mutant melanoma.
View Additional Section Content
For more information about our research program and IRB, please contact: